US › Healthcare

BioNTech SE (BNTX)

US · Healthcare · Biotechnology

$91.35-0.98%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$120.0M
Revenue YoY
-34.3%
Net profit
$-540.6M
Profit YoY
-30.0%
EPS
$-1.95
EPS estimate
$-1.92
Net margin
-450.4%

EPS came in at -1.95 against a street estimate of -1.92 — a miss of 1.6%.

Key statistics

Market cap
$22.91B
Forward P/E
7.0
P/B
1.07
Book value
$84.78
EPS (TTM)
$-5.82
52-week high
$124.00
52-week low
$79.52
50-day MA
$91.34
200-day MA
$98.22
Beta
1.32

Analyst view

Analysts rate BioNTech SE a buy (16 buy, 5 hold, 0 sell out of 21) with an average price target of $123.51.

Shareholding

Insiders
57.51%
Institutions
20.61%

Largest institutional holders

FundStake
T. Rowe Price Investment Management,Inc.2.32%
FMR Inc2.26%
PRIMECAP Management Company1.50%
Flossbach von Storch AG1.46%
Dodge & Cox1.45%
BlackRock Inc0.66%
BNP Paribas Arbitrage, SA0.65%
Temasek Holdings Ltd.0.60%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for BioNTech SE — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.